Cullinan Therapeutics

New Capabilities

Co-developing zipalertinib and planning a U.S. filing for the first-line combination

Patients with EGFR exon 20 insertion lung cancer have had almost no targeted options in the front-line setting. A phase 3 trial presented Sept. 13 in Seoul changed that. Adding the oral drug zipalertinib to chemotherapy delayed tumor progression by six months compared with chemotherapy alone.

Updated Yesterday